Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD (+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Stage of Development | 11 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Therapy Area | 12 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Indication | 13 | 2 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Companies | 17 | 6 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Products under Development by Universities/Institutes | 23 | 2 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Therapeutics Assessment | 25 | 6 |
| Assessment by Monotherapy/Combination Products | 25 | 1 |
| Assessment by Mechanism of Action | 26 | 1 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Companies Involved in Therapeutics Development | 31 | 15 |
| AbbVie Inc. | 31 | 1 |
| American Gene Technologies International Inc. | 32 | 1 |
| AstraZeneca Plc | 33 | 1 |
| BeiGene, Ltd. | 34 | 1 |
| Clovis Oncology, Inc. | 35 | 1 |
| Eisai Co., Ltd. | 36 | 1 |
| Hager Biosciences, LLC | 37 | 1 |
| IMPACT Therapeutics, Inc. | 38 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 39 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 40 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 41 | 1 |
| Nerviano Medical Sciences S.r.l. | 42 | 1 |
| Takeda Pharmaceutical Company Limited | 43 | 1 |
| Tesaro, Inc. | 44 | 1 |
| Teva Pharmaceutical Industries Ltd. | 45 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Drug Profiles | 46 | 47 |
| ABT-767 Drug Profile | 46 | 1 |
| AGPD Drug Profile | 47 | 1 |
| AZ-0108 Drug Profile | 48 | 1 |
| BGB-290 Drug Profile | 49 | 2 |
| CK-102 Drug Profile | 51 | 1 |
| E-7449 Drug Profile | 52 | 1 |
| fluzoparib Drug Profile | 53 | 1 |
| IMP-04297 Drug Profile | 54 | 1 |
| JPI-289 Drug Profile | 55 | 1 |
| MP-124 Drug Profile | 56 | 1 |
| niraparib Drug Profile | 57 | 4 |
| NMSP-118 Drug Profile | 61 | 1 |
| NMSP-648 Drug Profile | 62 | 1 |
| NMSP-914 Drug Profile | 63 | 1 |
| olaparib Drug Profile | 64 | 9 |
| R-503 Drug Profile | 73 | 2 |
| rucaparib phosphate Drug Profile | 75 | 7 |
| Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning Drug Profile | 82 | 1 |
| Small Molecule to Inhibit PARP-1 for Undisclosed Indication Drug Profile | 83 | 1 |
| Small Molecules to Inhibit PARP-1 for Colon Cancer Drug Profile | 84 | 1 |
| Small Molecules to Target PARP1, 2, 3 and NO for Oncology Drug Profile | 85 | 1 |
| veliparib Drug Profile | 86 | 5 |
| XZ-120312 Drug Profile | 91 | 1 |
| YHP-743 Drug Profile | 92 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Dormant Projects | 93 | 6 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Discontinued Products | 99 | 1 |
| Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Featured News &Press Releases | 100 | 15 |
| Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting | 100 | 3 |
| Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer | 103 | 2 |
| Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing | 105 | 1 |
| Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation | 105 | 1 |
| May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting | 106 | 1 |
| May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting | 107 | 1 |
| May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer | 108 | 1 |
| May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016 | 109 | 1 |
| Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer | 109 | 1 |
| Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting | 110 | 1 |
| Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting | 111 | 1 |
| Jan 28, 2016: Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer | 111 | 1 |
| Jan 27, 2016: NICE recommends olaparib for ovarian cancer | 112 | 1 |
| Jan 25, 2016: Clovis Oncology Names Dale Hooks as Chief Commercial Officer, Provides Update On Rucaparib | 112 | 1 |
| Dec 11, 2015: NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information | 113 | 2 |
| Appendix | 115 | 2 |
| Methodology | 115 | 1 |
| Coverage | 115 | 1 |
| Secondary Research | 115 | 1 |
| Primary Research | 115 | 1 |
| Expert Panel Validation | 115 | 1 |
| Contact Us | 115 | 1 |
| Disclaimer | 116 | 1 |